In summary, our investigation reveals that among ROS1-positive NSCLC patients treated with crizotinib as an initial therapeutic approach, PD-L1 expression may serve as an adverse prognostic marker for PFS rather than OS. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.